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Background: Isolated fucoidans from brown marine algae have been shown to have a range 
of anti-inflammatory effects.
Purpose: This present study tested a Maritech® extract formulation, containing a blend of extracts 
from three different species of  brown algae, plus nutrients in an open label combined phase I and II 
pilot scale study to determine both acute safety and efficacy in osteoarthritis of the knee.
Patients and methods: Participants (n = 12, five females [mean age, 62 ± 11.06 years] and 
seven males [mean age, 57.14 ± 9.20 years]) with a confirmed diagnosis of osteoarthritis of 
the knee were randomized to either 100 mg (n = 5) or 1000 mg (n = 7) of a Maritech® extract 
formulation per day. The formulation contained Maritech® seaweed extract containing Fucus 
vesiculosis (85% w/w), Macrocystis pyrifera (10% w/w) and Laminaria japonica (5% w/w) plus 
vitamin B6, zinc and manganese. Primary outcome was the average comprehensive arthritis test 
(COAT) score which is comprised of four sub-scales: pain, stiffness, difficulty with physical 
activity and overall symptom severity measured weekly. Safety measures included full blood 
count, serum lipids, liver function tests, urea, creatinine and electrolytes determined at baseline 
and week 12. All adverse events were recorded.
Results: Eleven participants completed 12 weeks and one completed 10 weeks of the study. 
Using a multilevel linear model, the average COAT score was reduced by 18% for the 100 mg 
treatment and 52% for the 1000 mg dose at the end of the study. There was a clear dose response 
effect seen between the two treatments (P  0.0005) on the average COAT score and each of 
the four COAT subscales (pain, stiffness, difficulty with physical activity and overall symptom 
severity) (P  0.05). The preparation was well tolerated and the few adverse events were unlikely 
to be related to the study medication. There were no changes in blood parameters measured 
over the course of the study with the exception of an increase in serum albumin which was not 
clinically significant.
Conclusion: The seaweed extract nutrient complex when taken orally over twelve weeks 
decreased the symptoms of osteoarthritis in a dose-dependent manner. It was demonstrated 
to be safe to use over the study period at the doses tested. The efficacy of the preparation now 
needs to be demonstrated in a phase III randomized controlled trial (RCT).
Australian and New Zealand Clinical Trials Register: ACTRN12607000229471.
Keywords: fucoidan, osteoarthritis, complementary medicine, inflammation, TNF alpha
Introduction
Osteoarthritis (OA) is the most frequent cause of disability among adults in the 
developed world. Arthritis affects around three million people in Australia, representing 
about 15% of the population.1 Similarly, more than 20 million people in the United 
States have the disease.2 The lifetime risk of knee OA for males and females aged over Biologics: Targets & Therapy 2010:4 34
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45 years in Johnston County is estimated at between 44.7% 
(nonobese) and 67% (obese) and these figures are believed 
to reflect the incidence of OA across the United States.3 OA 
costs more than $60 billion per year in the USA and is second 
only to ischemic heart disease as a cause of work disability 
in men aged over 50 years.4 The progressive deterioration of 
articular cartilage which occurs in OA results in pain, stiffness 
and difficulty with physical activities. The disease is managed 
rather than cured, with a focus on pain relief.5 A number of 
herbal medicines have been found to have beneficial effects 
in alleviating the symptoms of OA in human clinical studies. 
These include advocado, soybean unsaponifiables,6 lipids 
from green-lipped mussels,7 calcified seaweed extracts,8 and 
Pycnogenol (French maritime pine bark extract).9 Boswellia 
serrata extracts have also show clinical promise10 as do prepa-
rations of Harpagophytum procumbens (Devil’s Claw).11,12 
Polyphenols such as epigallocatetchin (from green tea) and 
phlorotannin-rich extracts of the seaweed Ecklonia cava have 
exhibited potential using in vitro models yet have generated 
little clinical evidence to date.13
In the Western herbal medicine tradition, bladderwrack 
(Fucus vesiculosus) and other seaweeds in the form of topi-
cally applied liniments have been used as herbal approaches 
to the treatment of sore knees.14 Seaweed extracts have been 
demonstrated to contain at least two major components with 
anti-inflammatory activity; fucoidans and polyphloroglucinols 
(algal polyphenols). Fucoidans are considered to be one of 
the main therapeutic components of brown algae15 and may 
constitute up to 25%–30% of the algal dry weight, depending 
on the specific seaweed species.16 Although fucoidans are 
highly branched long chain polysaccharides, low levels of 
serum uptake of fucoidan were observed after Undaria fucoi-
dan ingestion17 indicating that there is potential for clinical 
activity. Fucoidan is a potent selectin blocker and has been 
used experimentally to prevent inflammatory damage after 
ischemic events.18,19
Polyphenolic fractions derived from seaweed also have 
profound antioxidant activity20 which can also contribute to 
anti-inflammatory effects. Inhibition of oxalate damage to 
kidneys in animal models was attributed to the antioxidant 
qualities of Fucus-derived fucoidan.21 Fucoidans have been 
shown to inhibit phospholipase A2
22 an important enzyme in 
the inflammatory cascade inhibited by corticosteroids.
The toxicity of seaweed extracts has been investigated in 
both human and animal studies, although the source of the 
extracts has been different to the Fucus source used in this 
study. Previous human clinical studies using 3 g daily Undaria 
seaweed extracts with 75% fucoidan content indicated no 
clinically observed toxicity.23 In a recent companion study 
on the coagulation effects of 3 g of the same Undaria extract, 
there was a significant change in clotting indices, but these 
remained within clinically normal parameters. Activated 
partial thromboplastin time increased from 28.41 to 34.01 s 
(n = 10; P = 0.01), thrombin time decreased from 18.62 to 
17.55 s (n = 10, P = 0.04), and anti-thrombin-III increased 
from 113.5% to 117% (n = 10, P = 0.03).24 There were no 
toxicological changes observed in rats given up to 300 mg/kg 
orally of fucoidan from Laminaria japonica. This dose is 
considerably higher that the 3000 mg per subject dose in the 
clinical studies. The absence of observations may be because 
of difference in the source species for the fucoidan, or the 
absorption of the fucoidan from the gut. Anticoagulant effects 
were observed at doses of 900 to 2,500 mg/kg, but no other 
signs of toxicity were observed.25 In a similar study involv-
ing fucoidan extracted from Cladosiphon okamuranus, no 
significant toxicological changes were induced by fucoidan 
at a dose of 600 mg/kg of body weight/day in Wistar rats. 
However, with concentrations at and above 1,200 mg/kg of 
body weight/day, clotting time was significantly prolonged.26 
Overall, the dose levels used in this study (a total of either 
100 mg and 1000 mg per day) would not be expected to 
produce changes outside of the clinically normal parameters, 
as they are many fold lower than the dose levels used in the 
animal studies, and a third of the dose used in the human 
clinical study. A polyphenol rich fraction of Fucus was also 
shown to lack acute toxic effects in rats after four weeks of 
oral dosing.20 The latter extract was somewhat different to 
the extract used in this study as it contained a concentrated 
polyphenol fraction.
The present study tested a seaweed extract nutrient com-
plex containing a blend of extracts from three different spe-
cies of brown algae plus nutrients zinc, manganese and B6, 
using an open label design at two doses to determine effects 
in OA. This was a pilot scale combined phase I and II study 
aimed at providing data on acute safety and efficacy.
Material and methods
Research design
This trial was a pilot scale open label dosing study, with two 
different doses randomised to participants, conducted over 
12 weeks (84 days) in Lismore New South Wales (Australia) 
and was conducted in 2008. The study was approved by 
the Human Research Ethics Committee of Southern Cross 
University (Ethics approval number: ECN-07-36). The 
research was conducted in compliance with Good Clinical Biologics: Targets & Therapy 2010:4 35
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Practices (GCP) and in accordance with the guidelines 
of the Australian National Health and Medical Research 
Council and the Declaration of Helsinki (as revised in 2004). 
The trial was registered with the Australian and New Zealand 
Clinical Trials Register (ACTRN12607000229471).
Participants
A convenience sample of healthy individuals aged between 
18 and 65 years was recruited by email from staff and stu-
dents at Southern Cross University, and from Lismore and 
surrounding areas through newspaper advertising, regional 
radio and television. All participants received a study infor-
mation sheet outlining the study and signed an informed 
consent form agreeing to participate.
Participants were included if they had both X-ray and 
clinical evidence of osteoarthritis of the knees; if they 
had a baseline comprehensive osteoarthritis test (COAT) 
score between 3 and 7; were otherwise healthy (had no 
other acute nor chronic medical condition); and if they were 
willing to discontinue their current OA treatment for the 
duration of the study. Participants were excluded if they had 
a history of trauma associated with the affected joint; if they 
had rheumatoid arthritis or other inflammatory joint condi-
tions (including gout); if they used corticosteroids (intra-
articular or systemic) within four weeks prior to baseline and 
throughout the study; if they used anti-inflammatory agents 
or anti-arthritic complementary medicines three weeks prior 
to baseline and during the duration of the study; had liver 
function tests greater than three times the upper limit of nor-
mal at baseline; if they had a history of alcohol or substance 
abuse; were female participants who were lactating, pregnant 
or planning to become pregnant; if they had participated in 
another clinical trial in the last 30 days; if they were unwilling 
to have blood taken three times during the study; or if they 
were unwilling to comply with the study protocols.
Outcome measurements
The primary outcome measurement in this study were the 
safety measures and the average COAT score, a validated 
measurement instrument for the assessment of the symp-
toms of osteoarthritis.27 The COAT score is composed of 
four subscales: pain, stiffness, difficulty with physical 
activity and overall symptom severity. Secondary outcomes 
included the individual COAT sub-scales, TNF-alpha mea-
surements, serum lipids and paracetamol usage over the 
12 week study.
Baseline COAT measures were recorded and participants 
with visual analog scale (VAS) scores between 3 and 7 out 
of a possible 10 who agreed to wash out from their current 
osteoarthritis treatment were admitted to the study. Wash 
out commenced four weeks prior to the start of the trial 
and participants did not take their current osteoarthritis 
medications for the duration of the study. The participants 
were supplied with study diaries and asked to record their 
COAT scores and paracetamol use daily for four weeks. 
They were requested not to take narcotic analgesics and 
those containing codeine for seven days before the next 
clinic and until the end of the study. Study staff contacted 
the participants each week at the same time to ensure com-
pliance and provide support.
COAT scores included joint pain, stiffness, difficulty 
with physical activities and overall symptom score. The 
participants completed a baseline COAT score under the 
supervision of the clinic staff by making a mark on a 10 cm 
VAS with a single vertical line to show the severity of each 
descriptor over the past twenty-four hours. The descriptors 
were none to extreme with a numerical score of 0 to 10. The 
scores were converted to a numerical grade through measure-
ment with a ruler placed on the mark. Daily diaries were 
issued along with identical rulers (manufactured by Celco) 
and study staff contacted the participants each day at the 
same time to collect scores, ensure compliance and provide 
support. These instructions complied with the methods used 
with the validated tool. Participants were screened four weeks 
prior to the trial, they returned two weeks prior to ensure 
that scores remained between 3 and 7, and then returned at 
baseline. If the scores remained between 3 and 7 at baseline, 
the participant was randomised to a study medication.
Safety was assessed by actively monitoring adverse 
events. Subjects were questioned weekly about adverse 
events which were then recorded. Participants attended three 
clinics during which weight, blood pressure, pulse rate, and 
concomitant medication use was recorded and fasting blood 
samples collected at baseline, week 4, and week 12. Safety 
measurements undertaken by an independent accredited 
laboratory were full blood count, liver function tests and 
determination of urea, creatinine, electrolytes, cholesterol 
and triglyceride concentrations to assess toxicity to the hemo-
poietic, hepatic and renal systems; and assess the impact on 
fasting lipids. The body mass index (BMI) was calculated at 
the start and conclusion of the study.
Subjects returned all remaining capsules at each clinic 
visit and these were counted as a measure of compliance. The 
investigator maintained an inventory record of all capsules 
received and dispensed. It was assumed that capsules not 
returned were taken.Biologics: Targets & Therapy 2010:4 36
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Participants were asked at the end of the study to evaluate 
the study medication by answering a question indicating 
their satisfaction, dissatisfaction, or neither satisfaction 
nor dissatisfaction with the study medication.
study medication and dose
The study medication used Maritech® extract (Marinova 
Pty Ltd, Hobart, Australia). These are fucoidan-rich extracts 
of seaweeds (Maritech® extracts) which are manufactured 
using a proprietary aqueous process that produces fucoidan 
fractions. Nothing is added during the process. Insoluble 
matter and salts are removed as part of the process. They 
are ‘whole plant’ extracts which contain fucoidan and sea-
weed polyphenols (polyphloroglucinols) associated with the 
fucoidan molecule. In this study we used a blend of three 
Maritech® extracts from different species of brown sea-
weeds; Maritech® Fucus vesiculosis (85% w/w), Maritech® 
Macrocystis pyrifera (10% w/w) and Maritech® Laminaria 
japonica (5% w/w). In addition, Vitamin B6, zinc sulfate 
and manganese sulfate were included in the formulation, as 
detailed in Table 1. The study medication was manufactured 
as 100 mg and 250 mg capsules (Gel Caps) under the code 
of good manufacturing practice (GMP). The total fucoidan 
concentration in the 100 mg and 250 mg capsules was 75 mg 
and 187.5 mg respectively. Fucoidan content is assessed using 
a validated spectrophotometric method based on a modified 
Dubois method.28
Subjects were randomized to either a100 mg or 1000 mg 
dose group using the research randomizer website (http://
www.randomizer.org/). Seven sets of two numbers per set, 
using a range of one to two, were generated. These numbers 
were used to assign the participants to either the 100 mg or 
1000 mg dose. The 100 mg dose was delivered in one 100 mg 
gel capsule daily (taken in the morning) to five participants. 
The 1000 mg dose was delivered as four 250 mg capsules 
daily (two capsules taken twice daily) to seven participants. 
The capsules were self-administered orally by the participants 
after food.
TnF alpha assays
After collection serum was stored at -70 °C until analyzed. 
Serum tumor necrosis factor-α (TNF-α) was measured using 
a sandwich ELISA assay (Cayman Chemical Company, 
Denver, CO, USA). Thawed serum was supplemented with 
5% mouse serum and 9 mM dithiothreitol in order to mini-
mise nonspecific binding to the mouse anti-TNF-α. Serum 
was assayed without further dilution. TNF-α standards were 
prepared in TNF-α free human serum and similarly supple-
mented with mouse serum and dithiothreitol. Each sample 
was assayed in duplicate on two separate microplates (n = 4). 
Four samples had a single outlier removed. The standard 
curves for both plates had R2s of 0.99 over a concentration 
range of 0–250 pg/mL.
statistical methods
A multilevel repeated measures analysis with auto-correlated 
time was conducted on the average COAT score and each of 
the four COAT subscales over the 85 measurement occasions 
from baseline (day 0) to completion (day 84) using SPSS 
(version 17.0; SPSS Inc, Chicago, IL, USA) with the Mixed 
procedure with a first order autoregressive (AR1) covariance 
modeled on the daily repeated measurements. The model 
presented fitted a two-piece linear response over time29 with a 
change point at day 21, and included the effects of treatment, 
2-piece time, and 2-piece time by treatment interaction.
Results
study participants
The study screened volunteers and subsequently enrolled 
thirteen people who met the inclusion/exclusion criteria 
and were comprised of six females (mean age [±SD] 62.16 
[±9.04] years) and seven males (mean age [±SD] 57.14 
[±9.20] years). One subject withdrew a week prior to the 
start of the baseline measure due to an acute respiratory 
tract infection. Eleven participants completed 12 weeks of 
the study. One participant completed 10 weeks of the study 
due to overseas travel for the final 2 weeks and their final 
blood measurement was taken at week 10. Data was ana-
lysed for these 12 participants. Five participants received 
the formulation in doses of 100 mg Maritech® extract and 
seven received 1000 mg Maritech® extract. There was 99.2% 
compliance at four weeks and 99.6% at twelve weeks with 
participants taking 100 mg daily and 97.4% at four weeks 
and 95.9% compliance at twelve weeks in individuals tak-
ing 1000 mg per day. Please see Figure 1 for a flow diagram 
of the trial. The study medication was well tolerated as all 
12 participants were satisfied with the effects of taking the 
Table 1 contents of Maritech® capsules
Component 100 mg 250 mg
Maritech® Fucus vesiculosis 85 mg 212.5 mg
Maritech® Macrocystis pyrifera 10 mg 25 mg
Maritech® Laminaria japonica 5 mg 12.5 mg
Pyridoxine hydrochloride 57.50 mg 14.38 mg
Zinc sulphate monohydrate 25 mg 6.25 mg
Manganese sulphate 4 mg 1 mgBiologics: Targets & Therapy 2010:4 37
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study medication (compared with dissatisfied; or neither 
satisfied or dissatisfied).
The mean ages, and the baseline means for blood pres-
sure, weight and pulse rate for the 100 mg and 1000 mg arms 
were not statistically different (data not presented).
cOAT scores
Subjects taking either dose experienced reduction in COAT 
scores over the 12 weeks of the study. Means for the main 
outcome, the average of the COAT score subscales (average 
COAT), at baseline and on every seventh measurement 
occasion are provided for each treatment in Table 2 to 
summarize the response. A more complete description 
showing the daily mean average COAT scores is provided 
graphically in Figure 2 to which an empirical Loess curve 
was fitted to summarize the underlying response profiles. 
On observing Figure 2, two-piece linear functions with the 
break points at days 21 and 28 were tested in the statistical 
model for the Average COAT score, with the day 21 break 
point displaying superior fit in terms of the -2 log likeli-
hood fit statistics (2007.9 at 21 days and 2010.7 at 28 days). 
Table 3 reports the parameter estimates for the average 
COAT model and Figure 3 shows the estimated mean aver-
age COAT profiles by time by treatment. There was a highly 
significant treatment by time interaction effect (likelihood 
ratio test, chi-square = 15.155, df = 2, P = 0.0005), which 
was largely located after day 21 as indicated by the tests 
of the interaction parameters in Table 3. The parameter 
estimates are not reported for the pain, stiffness, physical 
difficulties and overall symptoms sub-scales but were 
similar to those obtained for the average COAT scale as 
would be expected from highly correlated variables. Table 4 
reports the estimated means for each of the COAT scales at 
baseline and completion for both treatments, and the results 
of a one-tailed test of the hypothesis that the reduction 
from baseline to completion was significantly greater in the 
1000 mg than the 100 mg treatment. This hypothesis was 
confirmed at P  0.05 for the average COAT (0.043) scale, 
and the physical difficulties (0.010) and overall symptoms 
(0.044) sub-scales, but failed to reach significance for the 
Assessed for eligibility
N = 27
Enrolment
Excluded N = 14
Not meeting inclusion criteria N = 3
Out of range COAT N = 11
Randomized
Allocated to 
1000 mg
N = 7
Allocated to 
100 mg
N = 6
Discontinued intervention
N = 1
Reason 
Influenza
Analyzed
N = 7 
Analyzed
N = 5
Figure 1 Flow diagram of trial organization.
Table 2 Average cOAT score: mean, standard deviation (sD), 
minimum and maximum at the weekly measurement occasions 
by treatment
Week 100 mg 1000 mg
N Mean SD Min Max N Mean SD Min Max
Baseline 5 4.54 1.02 3.25 6.00 7 5.32 0.94 4.33 7.00
1 5 4.25 2.07 2.00 6.38 7 4.10 1.62 1.75 6.93
2 5 4.30 1.92 2.00 6.25 7 3.62 0.82 2.25 4.50
3 5 3.88 1.25 3.00 6.00 7 3.39 1.44 0.88 5.50
4 5 3.68 1.79 2.00 6.00 7 3.06 1.69 0.00 4.50
5 5 3.73 1.44 2.00 6.00 7 3.15 1.66 0.00 5.00
6 5 3.88 1.54 2.00 6.00 7 3.61 2.11 0.25 7.05
7 5 3.68 1.70 2.00 6.00 7 2.79 1.49 0.88 5.00
8 5 4.40 1.66 2.00 6.38 7 2.71 1.62 0.00 5.00
9 5 4.13 1.56 2.00 6.25 7 2.64 1.86 0.00 5.50
10 5 3.70 1.71 2.00 6.25 7 2.83 1.82 0.00 5.00
11 4 3.59 1.90 2.00 6.25 7 2.65 2.08 0.00 5.50
12 4 3.63 1.87 2.00 6.25 7 2.27 1.95 0.00 5.00Biologics: Targets & Therapy 2010:4 38
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Table 3 Average COAT scores: parameter estimates with their standard errors and tests of significance
Parameter Estimate SE t value df P value
intercept (100 mg) 4.542 0.705 6.442 13.699 0.000
Treatment (1000 mg) 0.263 0.923 0.285 13.698 0.780
Time 0–21 (days) -0.036 0.018 -2.014 108.787 0.047
Time 21–84 -0.001 0.005 -0.227 87.490 0.821
Time 0–21 by treatment (1000 mg) -0.027 0.023 -1.166 108.725 0.246
Time 21–84 by treatment (1000 mg) -0.017 0.007 -2.539 87.311 0.013
Random: subject level variance 2.078 0.949 2.190 0.029
  Daily variance AR1 0.739 0.059 12.528 0.000
  rho AR1 0.680 0.025 26.749 0.000
Abbreviation: se, standard error.
pain (0.088) and stiffness (0.089) subscales. As shown in 
Table 4, mean average COAT reduced from 4.54 to 3.72 
(18%) in the 100 mg treatment and from 4.81 to 2.32 (52%) 
in the 1000 mg treatment.
Adverse events
Six adverse events were noted. The first event, influenza 
occurred prior to the commencement of the trial and the 
participant withdrew. Two participants had hypertension, 
one baseline and one at week 4. Both participants had a 
history of hypertension. One participant had a chest infection 
at week 12, one had root canal work at week 12, and one 
participant had hyperacidity at week 12 with a history of 
gastric acidity at baseline. All events were considered to be 
unlikely to be related to the study medication.
Blood safety measures
There were no toxicity issues observed over the period of 
the study hemopoietic, hepatic and renal systems. Due to the 
small numbers of participants in this study it is not possible 
to consider gender differences. Table 5 presents the mean, 
standard deviation (SD) and sample size for each blood 
safety measure at baseline and completion in each treatment 
and a test of the significance of the change. There were no 
statistically significant changes in either treatment over time 
although there was a statistically significant but not clinically 
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Figure 2 Average COAT score: daily mean by time by treatment with fitted Loess curves.Biologics: Targets & Therapy 2010:4 39
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Table 4 COAT scales: estimated baseline and completion means with 95% confidence intervals (ci) and tests of the difference in the reduction 
from baseline to completion between treatments
COAT scale Treatment Time Mean Lower  
95% CI
Upper 
95% CI
Average 100 mg Baseline 4.542 3.027 6.057
completion 3.717 2.236 5.199
1000 mg Baseline 4.805 3.524 6.086
completion 2.320 1.071 3.568
Test1 P = 0.043
Pain 100 mg Baseline 4.903 3.338 6.468
completion 3.827 2.300 5.355
1000 mg Baseline 4.786 3.464 6.109
completion 2.122 0.086 3.409
Test1 P = 0.088
stiffness 100 mg Baseline 4.853 3.334 6.371
completion 3.605 2.123 5.088
1000 mg Baseline 4.720 3.437 6.004
completion 2.339 1.090 3.588
Test1 P = 0.089
Physical difficulties 100 mg Baseline 3.805 2.313 5.297
completion 3.667 2.209 5.125
1000 mg Baseline 4.803 3.543 6.064
completion 2.401 1.173 3.629
Test1 P = 0.010
Overall 100 mg Baseline 4.614 3.078 6.149
completion 3.769 2.267 5.271
1000 mg Baseline 4.868 3.571 6.166
completion 2.413 1.147 3.678
Test1 P = 0.044
Note: 1One-tailed test of the hypothesis that the reduction in mean scores from baseline to completion is greater in the 1000 mg than the 100 mg treatment.
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Table 5 Blood safety measures: mean, standard deviation (sD) at baseline and completion 12 together with mean, sD, P-values for differences 
between baseline and completion by treatment
Baseline Week 12 Diff
N Mean SD Mean SD Mean SD P
Hematology
  Red cell count (x1012/L) 100 mg 5 4.88 0.35 4.82 0.25 0.06 0.17 0.468
1000 mg 7 4.70 0.30 4.71 0.32 -0.01 0.22 0.869
  hemoglobin (g/L) 100 mg 5 150.40 8.35 147.20 4.60 3.20 5.85 0.288
1000 mg 7 146.71 11.24 145.43 10.42 1.29 8.90 0.716
  hemacrit (%) 100 mg 5 0.44 0.03 0.44 0.02 0.00 0.02 0.799
1000 mg 7 0.43 0.03 0.43 0.03 -0.01 0.03 0.578
  Mean corpuscular volume (fL) 100 mg 5 90.20 2.68 78.00 27.50 12.20 26.19 0.356
1000 mg 7 91.00 1.83 91.14 1.86 -0.14 1.68 0.829
  White cell count (x109/L) 100 mg 5 5.76 0.98 5.84 1.30 -0.08 0.56 0.767
1000 mg 7 6.59 1.19 6.00 0.79 0.59 1.42 0.318
  Lymphocytes (x109/L) 100 mg 5 1.96 0.23 1.74 0.21 0.22 0.31 0.189
1000 mg 7 2.04 0.32 1.96 0.29 0.09 0.38 0.573
  Monocytes (x109/L) 100 mg 5 0.46 0.05 0.52 0.16 -0.06 0.15 0.426
1000 mg 7 0.46 0.16 0.47 0.05 -0.01 0.15 0.805
  neutrophils (x109/L) 100 mg 5 3.08 0.89 3.30 0.88 -0.22 0.36 0.240
1000 mg 7 3.89 0.77 3.37 0.65 0.51 0.93 0.192
  Basophils (x109/L) 100 mg 5 0.02 0.04 0.02 0.04 0.00 0.00
1000 mg 7 0.00 0.00 0.00 0.00 0.00 0.00
  eosinophils (x109/L) 100 mg 5 0.24 0.17 0.22 0.13 0.02 0.04 0.374
1000 mg 7 0.17 0.05 0.17 0.05 0.00 0.06 10.000
  Platelet count (x109/L) 100 mg 5 235.00 39.16 232.60 46.33 2.40 13.35 0.708
1000 mg 7 277.71 61.35 265.57 46.18 12.14 28.64 0.305
Biochemistry
  Alkaline phosphatase (u/L) 100 mg 5 68.20 6.76 64.80 7.66 3.40 3.13 0.072
1000 mg 7 71.71 8.44 68.14 12.95 3.57 11.72 0.451
  Alanine aminotransferase (u/L) 100 mg 5 22.80 6.06 30.80 8.90 -8.00 9.19 0.124
1000 mg 7 22.71 8.28 28.47 22.79 -5.76 15.64 0.368
  Aspartate aminotransferase (u/L) 100 mg 5 25.20 11.28 30.00 10.12 -4.80 10.06 0.346
1000 mg 7 21.14 4.41 23.86 5.70 -2.71 6.13 0.286
  Y-glutamyl transferase (u/L) 100 mg 5 27.80 16.50 27.40 12.22 0.40 5.37 0.876
1000 mg 7 33.29 17.07 39.71 35.99 -6.43 20.35 0.435
  Bilirubin (µmol/L) 100 mg 5 12.60 4.16 11.20 2.39 1.40 3.78 0.454
1000 mg 7 11.43 3.15 10.86 1.21 0.57 3.15 0.649
  Protein (g/L) 100 mg 5 70.80 6.14 71.00 6.36 -0.20 2.49 0.866
1000 mg 7 68.00 3.11 66.43 4.08 1.57 2.44 0.139
  Albumin (g/L) 100 mg 5 44.40 2.88 46.00 1.87 -1.60 2.19 0.178
1000 mg 7 43.00 1.00 43.57 1.13 -0.57 0.79 0.103
  sodium (mmol/L) 100 mg 5 138.80 0.45 139.80 0.84 -1.00 0.71 0.034
1000 mg 7 138.86 1.35 138.57 1.27 0.29 1.50 0.631
  Potassium (mmol/L) 100 mg 5 4.06 0.29 4.04 0.26 0.02 0.38 0.911
1000 mg 7 4.17 0.21 3.97 0.29 0.20 0.43 0.263
  chloride (mmol/L) 100 mg 5 104.00 2.45 105.80 2.68 -1.80 1.10 0.021
1000 mg 7 105.00 2.89 105.29 2.87 -0.29 2.43 0.766
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Table 5 (Continued    )
Baseline Week 12 Diff
N Mean SD Mean SD Mean SD P
BUn/Urea (mmol/L) 100 mg 5 7.00 1.27 6.12 0.88 0.88 1.49 0.258
1000 mg 7 5.77 1.08 6.34 0.82 -0.57 1.03 0.766
creatine (mmol/L) 100 mg 5 98.00 9.57 89.60 7.64 8.40 3.91 0.009
1000 mg 7 85.43 11.67 87.00 12.22 -1.57 11.57 0.732
Abbreviation: BUn, blood urea nitrogen.
significant increase in albumin over time for both treatments 
combined (P = 0.034).
Paracetamol use
Descriptive statistics for paracetamol use are reported in 
Table 6 together with Mann–Whitney tests comparing the 
treatments on use at baseline and total use over the duration 
of the trial. Weekly total paracetamol use (500 mg tablets) 
is plotted by treatment in Figure 4. None of subjects in the 
100 mg treatment took any paracetamol on the first day of 
treatment while, of the seven subjects in the 1000 mg treat-
ment, four took no paracetamol with the remaining three 
taking eight 500 mg tablets between them. The subjects in the 
100 mg treatment took a total of 58 tablets (each 500 mg) over 
the duration of the trial with individual consumption ranging 
from 0 to 40 tablets, while the subjects in the 1000 mg treat-
ment took a total of 152 tablets with individual consumption 
ranging from 0 to 62 tablets. Mann–Whitney comparisons 
of the two treatments showed no significant difference in 
consumption between the two groups either at baseline or 
over the duration of the trial.
TnF-α
Descriptive statistics for TNF-α are given in Table 7. There 
were no changes in TNF-alpha serum levels over time 
(P = 0.170), nor any differences between treatment groups 
(P = 0.227).
cholesterol and serum lipids
Repeated measures analysis of variance was conducted on the 
baseline and 12 week values for serum lipids. Descriptive data 
is given in Table 8. One subject in the 100 mg group did not 
have a recordable low-density lipoprotein (LDL) in week 12. 
There were no differences found between the doses.
Discussion
This study investigated the effects on the symptoms of osteo-
arthritis using two doses of a complex containing a blend of 
Maritech® extracts from three brown algae species (Fucus 
vesiculosis, Macrocystis pyrifera, Laminaria japonica.) plus 
vitamin B6, zinc and manganese in an open label design. 
There was a clear dose dependent effect on symptoms of 
osteoarthritis as assessed using the COAT index. The prepa-
ration was found to be safe at the doses used in the study 
population over 12 weeks.
After 12 weeks, the 100 mg dose reduced the average 
COAT score by 18% and the 1000 mg dose by 52%. 
The decrease in OA symptoms demonstrated by the 
1000 mg dose is marked. Whilst there is no direct 
comparator in this study, results expected from nonsteroid 
anti-inflammatory drugs (NSAIDS) produce similar 
reductions in OA symptoms.30 Osteoarthritis studies often 
have large placebo responses and a limitation of this early 
investigation was a lack of a placebo arm. The significant 
difference between the two doses in a dose-dependent 
progression increases the likelihood that the 1000 mg dose 
is superior to a placebo.
A recent randomised controlled study on a mineral based 
supplement derived from seaweed undertaken over 12 weeks 
demonstrated changes in the symptoms of osteoarthritis when 
measured by WOMAC.8 Although derived from a seaweed, 
the mineral-based supplement was substantially different 
Table 6 Paracetamol usage: mean, standard deviation (sD), and mean rank by treatment at baseline and over the duration of the trial 
with the Mann–Whitney P-values
100 mg 1000 mg Mann-Whitney
N Mean SD Mean rank N Mean SD Mean rank P
Baseline (Day 1) 5 0.00 0.00 5.00 7 1.14 1.57 7.57 0.205
Full trial (Day 1 to Day 84) 5 11.60 16.15 5.80 7 21.71 25.65 7.00 0.615Biologics: Targets & Therapy 2010:4 42
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from the soluble fucoidan-rich preparations used in this study, 
and cannot be directly compared.
Individuals with OA show raised levels of TNF-α,31 and 
we hypothesized that the seaweed formulation would demon-
strate a dose-dependent reduction over time as the fucoidans 
and polyphenols have been identified as anti-inflammatory 
agents. In this study, the TNF-α levels showed no change at 
either dosage perhaps indicating that the effect observed is 
not mediated via a TNF-α-associated cascade. However the 
study is not sufficiently powered to rule out a reduction in 
TNF-α, and further studies should include the measure.
Fucoidan is a major component of Maritech® seaweed 
extracts. It is not a precursor to mammalian tissue forma-
tion, and is generally assumed to be impervious to mam-
malian enzyme breakdown. Fucoidans have profound 
selectin-blocking activity,18 and serum uptake of fucoidan 
has been demonstrated previously.17 It is possible that, in this 
clinical trial, selectin-blocking effects may reduce leukocyte 
accumulation in the osteoarthritis affected areas, reducing the 
COAT scores via a generalized inhibition of inflammation. 
However paradoxically others have argued that selectin 
blockade may actually reduce pain relief.32 Further clinical 
trials and laboratory investigations are necessary to elucidate 
its mechanism of action.
The preparation was shown to be safe at the dosages 
consumed by the study population and any adverse effects 
were mild and self limiting. There were no changes in the 
cholesterol, liver function, renal function, and hemopoietic 
function that were of any clinical significance during the 
course of the study.
The most significant limitation of this study was; being 
a pilot scale open label combined phase I and II trial it was 
subject to potential bias that would be reduced by the use of 
randomization to placebo or active with appropriate blind-
ing. This study aimed to determine if this preparation had 
any potential in the treatment of the symptoms of osteoar-
thritis. The study achieved this aim and the significant dose 
responsiveness demonstrated provides evidence that these 
results are unlikely to be due to chance and deserve further 
exploration.
Conclusion
A seaweed extract nutrient complex when taken orally over 
twelve weeks significantly reduced the symptoms of osteo-
arthritis in a phase I and II open label study. The effect was 
highly dose-dependent with final reduction in COAT score of 
Table 7 Tumor necrosis factor alpha levels: means, standard deviation 
(sD), minima and maxima by treatment arm and measurement 
occasion
Occasion 100 mg 1000 mg
N Mean SD Min Max N Mean SD Min Max
Baseline 5 10.28 2.18 7.89 13.12 7 9.54 1.53 6.97 11.84
Week 4 5 9.08 2.24 7.20 12.74 7 9.66 1.43 6.93 11.44
Week 12 5 10.85 2.06 8.66 13.35 7 9.80 1.50 7.51 11.70
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18% and 52% respectively for the 100 mg and 1000 mg doses. 
The preparation was demonstrated to be safe to use over the 
study period at the doses tested in the study population. The 
observed pharmacological benefits now need to be demon-
strated in a phase III randomized controlled trial.
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